Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guanosine is a purine nucleoside composed of the base guanine attached to a ribose (ribofuranose) ring via a β-N9-glycosidic bond. It is an endogenous molecule that can be phosphorylated to form GMP, cGMP, GDP, and GTP—key intermediates in signal transduction pathways and essential for nucleic acid synthesis, protein synthesis, photosynthesis (in plants), muscle contraction, and intracellular signaling. In biological systems, it plays roles in RNA splicing reactions and as a precursor for several antiviral drugs. Experimentally and preclinically, exogenous administration of guanosine has shown neuroprotective effects in models of central nervous system diseases such as ischemic stroke, Alzheimer's disease, Parkinson's disease, spinal cord injury, nociception (pain), and depression. Its neurobiological actions are thought to involve activation of intracellular signaling pathways and interaction with the adenosinergic system[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on guanosine.